Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $455.45, denoting a -1% move from the preceding trading day.

The stock's fall snapped a three-day winning streak.

The biotech, known as the developer of the first CRISPR drug, will consolidate sites in the state as it stops developing a diabetes cell therapy.

Given that the Australian government heavily subsidizes pharmaceuticals— spending more than $AU16.7 billion annually through ...

THOU DOTH PORTEST — Protests are set to pop up around the Bay State this weekend, capping off a week of tension between the ...

Vertex is laying off 125 employees in Rhode Island and consolidating offices, following the discontinuation of a Type 1 ...

The Trump administration had said it would disclose by Wednesday the target prices for drugs, but pharma companies are still ...

Vertex Pharmaceuticals is getting bullish attention from analysts, especially Cantor Fitzgerald, which predicts earnings of ...

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company ...